ARCHIVES

European Compound enhances IL-2 In BRMP Mouse Study; BRMP Mouse Study; Rosemberg Describes System Improvements, Updates Results

This article is from The Cancer Letter archive.

Vol. 13 No. 23 | June 5, 1987

Download PDF Visit The Full Archive

Related Articles

Phase III Trial Of PARP Inhibitor BSI-201 Opens For Triple-Negative Breast Cancer

July 31, 2009

In Brief: NBCC Plans Meetings On Quality Of Care, Potential Environmental Causes Of Disease

February 20, 1998

West Virginia CCOP Will Be Funded; NASAU Joins Cincinnati As The Two Cut For Slow Patient Accrual

August 31, 1984

Phase III Trial Data: Lenvatinib Extends PFS by Over 14 Months

June 27, 2014

FDA Describes Meeting With NCI In “Limited” Memo

May 7, 1976

In Brief: General Murphy Resigns As Roswell Park Director; Penn.’s Richard Cooper Accepts Wisconsin Job

August 9, 1985